Organ systems

GBS Inc. Engages L.E.K. Consulting Hong Kong Pty Limited to Identify Potential Sublicensees in China for its Saliva-Glucose Diabetes Test

Retrieved on: 
Monday, July 26, 2021
Health, Organ systems, Diabetes, Disability, Clinical medicine

Consulting Hong Kong Pty Limited (L.E.K.

Key Points: 
  • Consulting Hong Kong Pty Limited (L.E.K.
  • Consulting) will be aiming to deliver and engage within two months a shortlist of suitable commercial partners for distribution in China.
  • Additionally, GBS found that patients in China indicated that price was not an issue, as long as the product was accurate and reliable.
  • Sublicensing to a knowledgeable and experienced commercial partner in the China region will allow GBS to provide the Saliva-Glucose Diabetes Test (SGBT) to the rapidly increasing diabetic population.

U.S Nationwide Commercial Availability of the VenSure™ Balloon Sinus Dilation System and Cube™ Navigation System Highlight Intersect ENT’s Continued Commitment to Providing Innovative, Solutions for Patients with Chronic Rhinosinusitis

Retrieved on: 
Monday, July 26, 2021
Medical devices, Health, Medical specialties, Headaches, Sinusitis, Rhinosinusitis, Sinus, Organ systems, Respiratory system, Intersect ENT, VenSure, INTERSECT ENT, VENSURE

The VenSure Balloon and Cube 4D Navigation Systems are used in procedures that are designed to improve debilitating chronic rhinosinusitis (CRS) symptoms.

Key Points: 
  • The VenSure Balloon and Cube 4D Navigation Systems are used in procedures that are designed to improve debilitating chronic rhinosinusitis (CRS) symptoms.
  • Balloon sinus dilation offers CRS patients a convenient, less-invasive, lower-cost solution by providing rapid resolution of symptoms with a minimal risk of complications.
  • The VenSure Sinus Balloon is a simple yet effective device with a slim, ergonomic design that tailors to the users hand for efficient maneuverability.
  • Accompanying the VenSure Sinus Balloon introduction is the Cube 4D Navigation system, a next generation electromagnetic navigation system that is intuitive, simple and precise.

Large Donation of COVID-19 Tests a Tremendous Help to Diabetes Summer Camps Across the Country

Retrieved on: 
Thursday, July 22, 2021
Diabetes, Organ systems, Health, Clinical medicine, Disability, Type 1 diabetes

GREENVILLE, S.C., July 22, 2021 /PRNewswire/ -- Many children with diabetes look forward to summer camp each year to, not only spend time with friends, but with other children who can relate to similar day-to-day obstacles that living with diabetes can present. The Diabetes Education and Camping Association (DECA) unites the global diabetes camping community, providing leadership, education, and resources to make camps for those with diabetes more impactful. As most summer camps across the US resumed this year, diabetes camps were faced with the extraordinary obstacle of protecting children who are at higher risk for COVID-19 complications due to diabetes. To bring summer camps for children living with diabetes back this year and to help protect these children, one of the nation's largest laboratories, Premier Medical Laboratory Services, donated thousands of COVID-19 tests to DECA camps in 19 states across the nation, enabling them to safely return to camp this year.

Key Points: 
  • As most summer camps across the US resumed this year, diabetes camps were faced with the extraordinary obstacle of protecting children who are at higher risk for COVID-19 complications due to diabetes.
  • "With diabetes being a global pandemic, it's a large focus for Premier Medical Laboratory Services to provide top healthcare solutions for patients with diabetes.
  • Terry Ackley, Executive Director of DECA added: "The safety of children with diabetes is the highest priority of diabetes camps.
  • Our community greatly appreciates their generous donation of a large quantity of rapid antigen tests to diabetes camps across the United States.

Global Graves Ophthalmopathy Market to 2030 - Insight, Epidemiology and Market Forecasts - ResearchAndMarkets.com

Retrieved on: 
Thursday, July 22, 2021
Health, Optical, Thyroid disease, Autoimmune diseases, Anatomy, Thyroid, Organ systems, Graves' ophthalmopathy, Organs anatomy), TED

The "Graves Ophthalmopathy - Market Insight, Epidemiology and Market Forecast - 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Graves Ophthalmopathy - Market Insight, Epidemiology and Market Forecast - 2030" report has been added to ResearchAndMarkets.com's offering.
  • The Graves Ophthalmopathy market report provides current treatment practices, emerging drugs, Graves Ophthalmopathy market share of the individual therapies, current and forecasted Graves Ophthalmopathy market Size from 2017 to 2030 segmented by seven major markets.
  • The Graves Ophthalmopathy market report gives a thorough understanding of the Graves Ophthalmopathy by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis and treatment.
  • The Graves Ophthalmopathy epidemiology division provide insights about historical and current Graves Ophthalmopathy patient pool and forecasted trend for every seven major countries.

Kadimastem Patent for cell selection of beta cells to Treat and Potentially Cure Diabetes was Granted in Japan

Retrieved on: 
Thursday, July 22, 2021
Clinical medicine, Organ systems, Branches of biology, Diabetes, Disability, Insulin, Type 1 diabetes

Cell therapy company Kadimastem Ltd ( TASE : KDST ) has received its patent approval from the Japanese Patent Office for IsletRx , the company's innovative treatment for diabetes.

Key Points: 
  • Cell therapy company Kadimastem Ltd ( TASE : KDST ) has received its patent approval from the Japanese Patent Office for IsletRx , the company's innovative treatment for diabetes.
  • This particular function of IsletRX is similar to a "healthy" pancreas and functions to treat insulin-dependent diabetes, such as Type 1 diabetes also known as juvenile diabetes.
  • The patent announced today protects Kadimastem's cell selection and enrichment technology, that enables it to identify and fortify the best cells in the expanded population.
  • Kadimastem CEO Asaf Shiloni said, "Receiving the patent in Japan further strengthens our intellectual property position.

Cyrex Announces Innovative New Immunophenotyping Test Panel, The Lymphocyte MAP™

Retrieved on: 
Wednesday, July 21, 2021
Branches of biology, Medical specialties, Organ systems, Immune system, Immunology, Lymphocyte, Biomarker

The Lymphocyte MAP measures the integrity of the immune system at the cellular level using 29 key biomarkers.

Key Points: 
  • The Lymphocyte MAP measures the integrity of the immune system at the cellular level using 29 key biomarkers.
  • The immunotyping of the test results is similar to a 3D view of the immune system, revealing important hidden patterns and trends.
  • The Lymphocyte MAP classifies an individuals immune response patterns into identifiable immunotypes for a better treatment regiment, explained Dr. Mark Engelman, director of clinical consulting at Cyrex Laboratories.
  • Additionally, the Lymphocyte MAP can determine if a patient is at risk of immunological disorders and potentially detect early warning signs of disease progression.

Arcutis Advances Science of Psoriasis Drug Development with New Precision Method for Measuring Mild-to-Moderate Psoriasis

Retrieved on: 
Wednesday, July 21, 2021
Organ systems, Autoimmune diseases, Medical specialties, Medicine, Psoriasis, Dermatitis, Seborrhoeic dermatitis, Eczema Area and Severity Index, Calcipotriol/betamethasone dipropionate

The article notes that disease severity is an essential outcome measure in clinical trials of new treatments for plaque psoriasis.

Key Points: 
  • The article notes that disease severity is an essential outcome measure in clinical trials of new treatments for plaque psoriasis.
  • However, the most common clinical measure to assess disease severitythe Psoriasis Area and Severity Index (PASI)is geared toward more-severe levels of disease.
  • In addition, PASI-HD more precisely captures disease flaring from and within areas with less than 10 percent of disease involvement.
  • The companys lead product candidate, topical roflumilast, has the potential to advance the standard of care for plaque psoriasis, atopic dermatitis, scalp psoriasis, and seborrheic dermatitis.

US Wet Age-Related Macular Degeneration Market and Competitive Landscape Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, July 21, 2021
Health, Optical, Macular degeneration, Senescence, Organ systems, Branches of biology, Stem cells, Monoclonal antibodies, Ophthalmology, Biology, Macular dystrophy, Macular scarring

The "US Wet Age-Related Macular Degeneration Market and Competitive Landscape - 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "US Wet Age-Related Macular Degeneration Market and Competitive Landscape - 2021" report has been added to ResearchAndMarkets.com's offering.
  • US Wet Age-Related Macular Degeneration Market and Competitive Landscape Highlights - 2021, provides comprehensive insights into Wet Age-Related Macular Degeneration pipeline products, Wet Age-Related Macular Degeneration epidemiology, Wet Age-Related Macular Degeneration market valuations and forecast, Wet Age-Related Macular Degeneration drugs sales and competitive landscape in the US.
  • Wet Age-Related Macular Degeneration pipeline: Find out the products in clinical trials for the treatment of Wet Age-Related Macular Degeneration by development phase 3, phase 2, and phase 1, by pharmacological class and companies developing the products
    Wet Age-Related Macular Degeneration epidemiology: Find out the number of patients diagnosed (prevalence) with Wet Age-Related Macular Degeneration in the US
    Wet Age-Related Macular Degeneration drugs: Identify key products marketed and prescribed for Wet Age-Related Macular Degeneration in the US, including trade name, molecule name, and company
    Wet Age-Related Macular Degeneration drugs sales: Find out the sales revenues of Wet Age-Related Macular Degeneration drugs in the US
    Wet Age-Related Macular Degeneration market valuations: Find out the market size for Wet Age-Related Macular Degeneration drugs in 2019 in the US.
  • Find out how the market advanced from 2017 and forecast to 2026
    Wet Age-Related Macular Degeneration drugs market share: Find out the market shares for key Wet Age-Related Macular Degeneration drugs in the US
    Evaluate commercial market opportunity assessment, positioning, and segmentation for Wet Age-Related Macular Degeneration products
    View source version on businesswire.com: https://www.businesswire.com/news/home/20210721005713/en/

US Macular Edema Market and Competitive Landscape Report 2021: Epidemiology, Key Products Marketed, Market Valuations and Forecast, Drugs Sales and Market Shares 2017-2026 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, July 21, 2021
Health, Other Health, Macular edema, Clinical medicine, Organ systems, Medicine

US Macular Edema Market and Competitive Landscape Highlights - 2021, provides comprehensive insights into Macular Edema pipeline products, Macular Edema epidemiology, Macular Edema market valuations and forecast, Macular Edema drugs sales and competitive landscape in the US.

Key Points: 
  • US Macular Edema Market and Competitive Landscape Highlights - 2021, provides comprehensive insights into Macular Edema pipeline products, Macular Edema epidemiology, Macular Edema market valuations and forecast, Macular Edema drugs sales and competitive landscape in the US.
  • The research is classified into seven sections - Macular Edema treatment options, pipeline products, market analysis comprising of epidemiology, key products marketed, market valuations and forecast, drugs sales and market shares.
  • Macular Edema pipeline: Find out the products in clinical trials for the treatment of Macular Edema by development phase 3, phase 2, and phase 1, by pharmacological class and companies developing the products
    Macular Edema drugs: Identify key products marketed and prescribed for Macular Edema in the US, including trade name, molecule name, and company
    Macular Edema market valuations: Find out the market size for Macular Edema drugs in 2019 in the US.
  • Find out how the market advanced from 2017 and forecast to 2026
    Macular Edema drugs market share: Find out the market shares for key Macular Edema drugs in the US
    Evaluate commercial market opportunity assessment, positioning, and segmentation for Macular Edema products

US Diabetic Retinopathy Market and Competitive Landscape Report 2021: Epidemiology, Key Products Marketed, Market Valuations and Forecast, Drugs Sales and Market Shares - ResearchAndMarkets.com

Retrieved on: 
Wednesday, July 21, 2021
Health, Optical, Diabetes, Blindness, Diabetic retinopathy, Organ systems, Retinopathy

US Diabetic Retinopathy Market and Competitive Landscape Highlights - 2021, provides comprehensive insights into Diabetic Retinopathy pipeline products, Diabetic Retinopathy epidemiology, Diabetic Retinopathy market valuations and forecast, Diabetic Retinopathy drugs sales and competitive landscape in the US.

Key Points: 
  • US Diabetic Retinopathy Market and Competitive Landscape Highlights - 2021, provides comprehensive insights into Diabetic Retinopathy pipeline products, Diabetic Retinopathy epidemiology, Diabetic Retinopathy market valuations and forecast, Diabetic Retinopathy drugs sales and competitive landscape in the US.
  • The research is classified into seven sections - Diabetic Retinopathy treatment options, pipeline products, market analysis comprising of epidemiology, key products marketed, market valuations and forecast, drugs sales and market shares.
  • Diabetic Retinopathy pipeline: Find out the products in clinical trials for the treatment of Diabetic Retinopathy by development phase 3, phase 2, and phase 1, by pharmacological class and companies developing the products
    Diabetic Retinopathy drugs: Identify key products marketed and prescribed for Diabetic Retinopathy in the US, including trade name, molecule name, and company
    Diabetic Retinopathy market valuations: Find out the market size for Diabetic Retinopathy drugs in 2019 in the US.
  • Find out how the market advanced from 2017 and forecast to 2026
    Diabetic Retinopathy drugs market share: Find out the market shares for key Diabetic Retinopathy drugs in the US
    Evaluate commercial market opportunity assessment, positioning, and segmentation for Diabetic Retinopathy products